Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Applied filters
Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 96-B, Issue SUPP_11 | Pages 110 - 110
1 Jul 2014
Yu Y Ibrahim N Yang J Walsh WR
Full Access

Summary Statement

Combination of sorafenib with irradiation achieved synergistic effect with dose reduction in both 143B and HOS cell lines. This demonstrated the potential application of sorafenib in the treatment of osteosarcoma metastasis and radiation resistance.

Introduction

More than 20% of patients with osteosarcoma die of the disease within 5 years due to tumour relapse and metastasis. Identifying new treatment that works singly or in combination with conventional therapies is urgently required. We previously found that the Ras/Raf/MAPK pathway was associated with lung metastasis in a 143B inoculated osteosarcoma orthotopic mouse model1. Sorafenib, a multi-kinase inhibitor, has shown potent anticancer effect including in osteosarcoma2 through the inhibition of Raf-1 and other targets3. The aims of this study were to investigate effect of sorafenib on osteosarcoma cell lines with or without activated Ras/Raf/MAPK signalling and to decide whether sorafenib could enhance irradiation on these cells.